Biopharma execs sign on to tout UK's R&D work

A high-profile crew of biopharma execs are signing on to help promote the life sciences industry in the UK. Chris Brinsmead, president of AstraZeneca U.K., will chair a 12-man strategy group for UK Trade & Investment to scout overseas markets for the U.K.'s life sciences industry while recruiting overseas investors. The life sciences industry is one of five sectors getting some muscular promotional support. And with the largest pipeline for new products in Europe, the country feels it has plenty to boast about.

"The UK is Europe's top location for research and development and a global hub for scientific research, but retaining this position in the face of growing competition from abroad is a significant challenge," Lord Digby Jones, the UK's trade minister, told The Times.

- read the report from The Times

Related Articles:
Market volatility spurs M&A talks at UK biotechs. Report
U.K. to require more disclosure of drug trial data. Report
U.K. researchers driven out by tough regulations. Report
GSK looks abroad for more scientists as U.K. shortage grows. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.